# Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

> **NCT07248670** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 252 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** metronomic adjuvant chemotherapy with capecitabine

## Key facts

- **NCT ID:** NCT07248670
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-04
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07248670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07248670, "Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07248670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*